Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin
DRUG: GSK3174998
DRUG: Feladilimab
DRUG: Nirogacestat
DRUG: Dostarlimab
DRUG: Isatuximab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Pomalidomide

Sponsor

GlaxoSmithKline